Reference
Summary Safety Review - Tagrisso (osimertinib) - Assessing the Potential Risk of Rhabdomyolysis and Other Myopathy-related Events Internet Document : 4 Sep 2023. Available from: URL: https://dhpp.hpfb-dgpsa.ca/review-documents/resource/SSR1690380271165
Rights and permissions
About this article
Cite this article
Osimertinib-related risk of rhabdomyolysis, myositis and elevated CPK. Reactions Weekly 1973, 3 (2023). https://doi.org/10.1007/s40278-023-45731-3
Published:
Issue Date:
DOI: https://doi.org/10.1007/s40278-023-45731-3